



Treasurer's report  
ALTG Members' Meeting  
17<sup>th</sup> August 2016



*"When you can't breathe...nothing else matters"*<sup>TM</sup>



Income	Expenditure
<p>Grants – expiring funds administered by USYD</p> <ul style="list-style-type: none"><li>• Cancer Australia (Ca Aus)</li><li>• CI NSW</li></ul>	<p>CTC trials development – funded by Ca Aus/CINSW</p> <ul style="list-style-type: none"><li>• Salaries – RFs and other staff</li><li>• Travel/meetings</li><li>• Hospital sites/other groups</li><li>• Other costs</li></ul>
<p>Clinical trials – project specific funds administered by USYD</p>	<p>CTC trials management</p> <ul style="list-style-type: none"><li>• Salaries – RFs and other staff</li><li>• Travel/meetings</li><li>• Hospital sites/other groups</li><li>• Other costs</li></ul>
<p>LFA/ALTG non-expiring funds</p> <ul style="list-style-type: none"><li>• RIBG</li><li>• Sponsorship</li><li>• Donations</li><li>• ALTG infrastructure from trials</li></ul>	<p>ALTG costs funded by Ca Aus expiring funds and ALTG non-expiring funds</p> <ul style="list-style-type: none"><li>• LFA infrastructure eg TCs, IT, rent, insurance</li><li>• Staff costs</li><li>• Travel grants/preceptorship costs</li><li>• Meetings/clinical trial design</li><li>• Consumer support</li><li>• Clinical trial insurance</li></ul>

# Income January to December 2015




• Grant income (held by USYD)	\$535,000
• Cancer Australia	\$460,000
• CINSW	\$75,000
• Clinical trials (held by USYD)	\$473,437
• NITRO	\$173,437
• BR31	\$300,000
• Non-expiring (held by LFA)	\$114,091
• RIBG	\$38,372
• Sponsorship	\$64,310 (P/ship & LCNP)
• BR31	\$11,225 (1x mtg)
• Donations	\$184



*"When you can't breathe...nothing else matters"*<sup>TM</sup>

# Expenditure January to December 2015



- **CTC trial dev't \$570,551**

• Staff	\$348,860
• Hosp/ext gps	\$196,625*
• Other costs	\$25,066

- **CTC trial mgt \$323,717**

• Staff	\$214,854
• Hosp/ext gps	\$26,500
• Other costs	\$82,363

\*Transfer of Ca Aus funds to ALTG

- **ALTG (Ca Aus) \$193,252**

• LFA	\$34,900
• Staff	\$103,516
• Travel Grants	\$21,369
• Meeting Costs	\$20,391
• Clin trial design	\$9,792
• Consumers	\$3,284


- **ALTG (LFA) \$78,972**

• BR31 lx mtg	\$11,225
• Preceptorship	\$44,169
• TACT	\$10,000
• Shine A Light	\$7,728
• Insurance/audit	\$5,850



*"When you can't breathe...nothing else matters"*<sup>TM</sup>

# Actuals January to December 2015



Description	Account Name	Opening Balance	Actual Income	Actual Expenditure	Closing Balance
		(Jan 15)	(Jan 15 – Dec 15)	(Jan 15 – Dec 15)	(Dec 15)
<b>INFRA-STRUCTURE GRANTS</b>	Cancer Australia	75,498	460,000	462,761	72,737
	CINSW	29,417	75,000	104,417	0
<b>LFA NON-EXPIRING FUNDS</b>	Lung Foundation	110,767	114,091	78,972	145,886
<b>TRIALS</b>	NITRO	-86,489	173,437	93,004	(6,056)
	B2P2M2	229,562	0	0	229,562
	BR26	53,649	0	12,274	41,375
	BR31	0	300,000	218,439	81,561
<b>TOTAL</b>		412,404	1,122,528	969,867	565,065



*"When you can't breathe...nothing else matters"*<sup>™</sup>

# Income January to June 2016



• Grant income (held by USYD)	\$179,121
• Cancer Australia	\$150,000
• CINSW	\$29,121
• Clinical trials (held by USYD)	\$1,005,906
• NITRO	\$90,097
• BR31	\$17,710
• NIVORAD	\$300,000
• PEARL	\$598,099
• Non-expiring (held by LFA)	\$120,893
• RIBG	\$0
• Sponsorship	\$120,000 (P/ship & LCNP)
• Trial payments	\$0
• Donations	\$893



*"When you can't breathe...nothing else matters"*<sup>TM</sup>

# Expenditure January to June 2016



- **CTC trials dev't \$225,085**

• Staff	\$150,817
• Travel/meetings	\$0
• Hosp/ext gps	\$62,104*
• Other costs	\$12,164

- **CTC trials mgt \$323,189**

• Staff	\$178,768
• Hosp/ext gps	\$24,000
• Other costs	\$129,421

- **ALTG (Ca Aus) \$88,881**

• LFA	\$17,450
• Staff	\$52,021
• Travel Grants	\$5,575
• Meeting Costs	\$10,911
• Clin trial design	\$208
• Consumers	\$2,716

- **ALTG (LFA) \$25,000**

• TACT	\$10,000
• LFA levy	\$15,000

\*Transfer of Ca Aus funds to ALTG



*"When you can't breathe...nothing else matters"*<sup>TM</sup>

# Actuals January to June 2016



Description	Account Name	Opening Balance	Actual Income	Actual Expenditure	Closing Balance
<b>INFRA-STRUCTURE GRANTS</b>	Cancer Australia	72,737	150,000	222,737	0
	CINSW	0	29,121	29,121	0
<b>LFA NON-EXPIRING FUNDS</b>	Lung Foundation	145,886	120,893	25,000	241,779
<b>TRIALS</b>	NITRO	-6,056	90,097	40,322	43,719
	B2P2M2	229,562	0	3	229,559
	BR26	41,375	0	21,161	20,214
	BR31	81,561	17,710	127,036	-27,765
	NIVORAD	0	300,000	136,486	163,514
	PEARL	0	598,099	7,184	590,915
<b>TOTAL</b>		565,065	1,305,920	609,050	1,261,935



# Forward estimates 2H 2016



	LFA/ALTG	USYD
Opening balance	\$241,779	\$1,020,152
Income Cancer Australia	\$129,650	\$310,000
Income from trials	\$181,510	E\$1,800,000
B2P2M2	\$90,000	
BR31	\$20,000	
NIVORAD	\$43,998	
DREAM	\$27,512	
Sponsorship and non-expiring income	\$393,311	
2 <sup>nd</sup> ALTG Preceptorship	\$100,000	
Lung cancer symposium	\$265,000	
RIBG	\$14,000	
Total income	\$946,250	E\$3,130,152
Expenditure	\$557,207	\$310,000 (Ca Aus) + trials
Closing balance	\$389,043	